52.1 F
New York
Tuesday, September 22, 2020

The Forecast Just Changed on BioXcel Therapeutics Inc. (NASDAQ:BTAI)

Must read

The Hartford Financial Services Group Inc. (NYSE:HIG) Finding Zero Support

The Hartford Financial Services Group Inc. (HIG) shares are trading at lower $37.25 and the avg recommendation for the stock is Moderate Buy. while...

LiveXLive Media Inc. (NASDAQ:LIVX) on the Path to Profitability

LiveXLive Media Inc. (LIVX) shares are trading at higher $3.02 and the avg recommendation for the stock is Strong Buy. To add more color...

Investor Confidence is Falling for Expedia Group Inc. (NASDAQ:EXPE)

Expedia Group Inc. (EXPE) shares are trading at lower $93.80 and the avg recommendation for the stock is Moderate Buy. while the current analyst...

The Unprecedented Rise of HighPoint Resources Corporation (NYSE:HPR)

HighPoint Resources Corporation (HPR) shares are trading at lower $0.28 and the avg recommendation for the stock is Moderate Buy. To add more color...

The BioXcel Therapeutics Inc. (BTAI) shares are trading at lower $52.54 and the avg recommendation for the stock is Strong Buy.

To add more color to this target, the company’s high over the last year is $71.50 and the low is $3.76. Over the last 52 weeks, BTAI is down -26.52% while the S&P 500 is down -0.63%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, BTAI reported a profit of $85000.0. BioXcel Therapeutics Inc. also saw revenues increase to $15.0 million. In addition, BTAI has free cash flow of -$12.17 million as of 03-2020. The company’s EBITDA came in at -$14.95 million which compares well with its peers.

BTAI Return on Equity (ROE) is -102.30%, and its Return on Assets is -81.30%. All told, it is clear that, BTAI needs to be on your watchlist.

Find out when BTAI reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. BTAI has a short ratio of 4.25 and outstanding shares of 18.97M.

Company Outlook

BTAI has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.96 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -2.36. BioXcel Therapeutics Inc. BTAI also noted assets of $85.81 million at the end of the last quarter. Investors should also keep an eye on sector updates as BTAI has historically followed its peers on positive news.

All told, BioXcel Therapeutics Inc. BTAI has strung together solid data and demonstrated underlying fundamentals. At its current valuation, BTAI represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

BioXcel Therapeutics Inc. BTAI is now commanding a market cap of 1.08B and a float of 10.48M. BTAI is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of BTAI stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in BTAI, either long or short, and we have not been compensated for this article.

Latest article

Pentair plc (NYSE:PNR) on the Path to Profitability

Pentair plc (PNR) shares are trading at higher $46.55 and the avg recommendation for the stock is Moderate Buy. while the current analyst price...

Is Now the Time to Invest in EPR Properties (NYSE:EPR)?

EPR Properties (EPR) shares are trading at lower $29.75 and the avg recommendation for the stock is Moderate Buy. while the current analyst price...

Omega Healthcare Investors Inc. (NYSE:OHI) Stock is Plummeting, Here is Why

Omega Healthcare Investors Inc. (OHI) shares are trading at lower $31.28 and the avg recommendation for the stock is Moderate Buy. while the current...

StoneMor Inc. (NYSE:STON) is Holding Steady

StoneMor Inc. (STON) shares are trading at higher $1.11. To add more color to this target, the company’s high over the last year is...

Investor Confidence is Falling for Soleno Therapeutics Inc. (NASDAQ:SLNO)

Soleno Therapeutics Inc. (SLNO) shares are trading at lower $1.94 and the avg recommendation for the stock is Strong Buy. To add more color...